Literature DB >> 2402182

Morphine-3-glucuronide--a potent antagonist of morphine analgesia.

M T Smith1, J A Watt, T Cramond.   

Abstract

In this study, morphine-3-glucuronide (M3G), the major plasma and urinary metabolite of morphine, was shown to be a potent antagonist of morphine analgesia when administered to rats by the intra-cerebroventricular (i.c.v.) route. The antagonism of morphine analgesia was observed irrespective of whether i.c.v. M3G (2.5 or 3.0 micrograms) was administered 15 mins prior to or 15 mins after i.c.v. morphine (20 micrograms). When M3G (10mg) was administered intraperitoneally (i.p.) to rats 30-40 mins prior to morphine (1.5mg i.p.), the analgesic response was significantly reduced compared to administration of morphine (1.5mg i.p.) alone. It was further demonstrated that i.c.v. M3G (2.0 micrograms) antagonized the analgesic effects of subsequently administered i.c.v. morphine-6-glucuronide (0.25 micrograms).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2402182     DOI: 10.1016/0024-3205(90)90619-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  62 in total

1.  Morphine induced allodynia in a child with brain tumour.

Authors:  S Heger; C Maier; K Otter; U Helwig; M Suttorp
Journal:  BMJ       Date:  1999-09-04

Review 2.  Integration of palliative care in chronic critical illness management.

Authors:  Judith E Nelson; Aluko A Hope
Journal:  Respir Care       Date:  2012-06       Impact factor: 2.258

3.  Increased clearance of morphine in sickle cell disease: implications for pain management.

Authors:  Deepika S Darbari; Michael Neely; John van den Anker; Sohail Rana
Journal:  J Pain       Date:  2011-02-01       Impact factor: 5.820

4.  Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.

Authors:  T J Wilkinson; B A Robinson; E J Begg; S B Duffull; P J Ravenscroft; J J Schneider
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Plasma morphine-3-glucuronide, morphine-6-glucuronide and morphine concentrations in patients receiving long-term epidural morphine.

Authors:  J J Schneider; P J Ravenscroft; J D Cavenagh; A M Brown; J P Bradley
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

6.  Intranasal delivery--modification of drug metabolism and brain disposition.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 7.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 8.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

9.  A successful case in cancer pain management with high-dose intravenous morphine.

Authors:  T Ishikawa; K Hiraga
Journal:  J Anesth       Date:  1995-12       Impact factor: 2.078

10.  Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

Authors:  J Hasselström; J Säwe
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.